RNA Supply Chain Resources
-
Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow
4/18/2022
We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.
-
Key Challenges for CRISPR In Clinical Development
2/28/2023
Learn how to approach CRISPR cell and gene therapy development challenges, such as regulatory hurdles, ensuring consistency, finding qualified and experienced staff, and obtaining GMP-Grade reagents.
-
Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions
4/21/2021
Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.
-
Revolutionizing Patient-Centric Supply Chains To Improve Vaccine Access
3/1/2023
Transparent collaboration and innovation are essential to establishing an infrastructure that supports more agile business models and empowers widespread vaccine access.
-
The Evolution Of Nucleotide Production
4/2/2025
From harsh chemicals to gentle enzymes: Explore the groundbreaking shift in nucleotide synthesis, making drug manufacturing cleaner, greener, and more efficient.
-
Optimization Of Transient Transfection Of MSCs With Plasmid DNA Or mRNA
11/1/2022
Read through the results of our efforts to produce an optimal protocol for the transient transfection of hMSCs with pDNA or mRNA using non-viral means.
-
Enabling CDMOs To Focus On Core Priorities
4/26/2024
Explore innovative solutions for CDMO's striving to remain competitive as the biopharmaceutical market grows and evolves.
-
Overcome The Supply Chain Complexities Of Vaccine Development
11/18/2022
Explore the industry impact of rapidly evolving vaccinology, the power of next-gen science and technology, and how finding the right supply chain partner has never been more essential.